|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Probiotic effects on intestinal fermentation patterns in patients with irritable bowel syndrome显示文摘AIM: To determine whether Lactobacillus casei strain Shirota (Yakult ) can alter small intestinal bacterial overgrowth (SIBO), as tested by the lactulose breath test, and whether this is associated with changes in symptoms in irritable bowel syndrome (IBS). METHODS: 18 patients with IBS (Rome Ⅱ criteria), who showed an early rise in breath hydrogen with lactulose (ERBHAL), consumed 65 mL of Yakult daily for 6 wk. Lactulose breath test was repeated at the end of the treatment period. Symptoms were recorded daily using a 10 cm visual analogue scale. RESULTS: 14 patients completed the study, 9 (64%) had reversal of ERBHAL, with the median time of f irst rise in breath hydrogen increasing from 45 to 75 min (P = 0.03). There was no signifi cant improvement in the symptom score with probiotic therapy, except for wind (P=0.04). Patients commencing with at least moderate symptoms and who no longer had ERBHAL at the end of treatment, showed improvement in the overall symptoms scores [median fi nal score 5.3 (IQR3.9-5.9), 55% reduction; n=6] to a greater extent than those who had had persisting ERBHAL [final score 6.9 (5.0-7.0), 12% reduction; n = 5; P = 0.18]. CONCLUSION: Yakult is effective in altering fermentation patterns in the small bowel, consistent with reducing SIBO. The loss of ERBHAL was associated with reduced symptoms. The true interpretation of these fi ndings awaits a randomised, controlled trial. | Jacqueline S Barrett Kim EK Canale Richard B Gearry Peter M Irving Peter R Gibson | 2008 | World Journal of Gastroenterology2008，14，32： | 16 |
| 2 | One fifth of hospitalizations for peptic ulcer-related bleeding are potentially preventable显示文摘AIM:To calculate the proportion of potentially preventable hospitalizations due to peptic ulcer disease(PUD),erosive gastritis(EG)or duodenitis(ED).METHODS:Retrospective cohort study using ICD-10codes to identify all patients with upper gastrointestinal hemorrhage secondary to endoscopically proven PUD,EG or ED during the period from March 2007 to October 2010 in three major metropolitan hospitals in Melbourne,Australia.Patients were divided into'high risk'(those who would benefit from gastroprotection)and'not high risk'groups as defined by established guidelines.Mean Rockall score,transfusion requirement,length of stay,rebleeding rates,need for surgery and in-hospital mortality was compared between'high risk'and'not high risk'groups.Within the'high risk'group,those on gastroprotection and those with no gastroprotection were also compared.RESULTS:Five hundred and seven patients were included for analysis of which 174 were classified as high risk.Median values of complete Rockall Score(5vs 4,P=0.002)and length of stay(5 d vs 4 d,P=0.04)were higher in the high risk group but in-hospital mortality was lower(0.6%vs 3.9%,P=0.03).130out of the 174 patients in the high risk group were not taking recommended gastroprotective therapy prior to hospitalization.Past history of PUD(OR=3.7,P=0.006)and clopidogrel use(OR=3.2,P=0.007)significantly predicted prescription of gastroprotective therapy.Using proton pump inhibitor protection rates of 50%-85%from published studies,an estimation of13%to 22%of the total number of the hospitalizations due to PUD or EG/ED related bleeding may have been preventable.CONCLUSION:Up to one fifth of all hospitalizations for bleeding secondary to PUD or EG/ED are potentially preventable. | Ray Boyapati Sim Ye Ong Bei Ye Anuk Kruavit Nora Lee Rhys Vaughan Sanjay Nurkar Peter Gibson Mayur Garg | 2014 | World Journal of Gastroenterology2014，20，30： | 8 |
| 3 | Subcutaneous Golimumab Induces Clinical Response and Remission in Patients with Moderate-To-Severe Ulcerative Colitis显示文摘 | William J. Sandborn Brian G. Feagan Colleen Marano Hongyan Zhang Richard Strauss Jewel Johanns Omoniyi J. Adedokun Cynthia Guzzo Jean-Frederic Colombel Walter Reinisch Peter R. Gibson Judith Collins Gunnar J?rnerot Toshifumi Hibi Paul Rutgeerts | 2013 | Gastroenterology2013，，： | 6 |
| 4 | Subcutaneous Golimumab Maintains Clinical Response in Patients with Moderate-To-Severe Ulcerative Colitis显示文摘 | William J. Sandborn Brian G. Feagan Colleen Marano Hongyan Zhang Richard Strauss Jewel Johanns Omoniyi J. Adedokun Cynthia Guzzo Jean-Frederic Colombel Walter Reinisch Peter R. Gibson Judith Collins Gunnar J?rnerot Paul Rutgeerts | 2013 | Gastroenterology2013，，： | 5 |
| 5 | 抗炎介质表达缺陷参与中性粒细胞型支气管哮喘发病机制:半乳糖凝集素-3和白细胞介素-1RA/白细胞介素-1beta比例显著下降显示文摘支气管哮喘(哮喘)是具有异质性的气道炎症性疾病,其主要特点表现为气道高反应和可变的气流受限。在哮喘的发病机制中,过敏原诱导的TH2淋巴细胞激活以及IL-5介导的嗜酸粒细胞渗出起到重要的作用。近年来发现超过50%的哮喘患者气道的嗜酸粒细胞水平并不增高,并将这种亚型定义为非嗜酸粒细胞型哮喘。其中部分患者表现为气道中性粒细胞明显增高,称为中性粒细胞型哮喘。 | 高鹏 Peter G Gibson Katherine J Baines Ian A Yang John W Upham Paul N Reynolds Sandra Hodge Alan L James Christine Jenkins Matthew J Peters 张捷 Jodie L Simpson | 2016 | 中华结核和呼吸杂志2016，39，11： | 5 |
| 6 | Time to clinical response and remission for therapeutics in inflammatory bowel diseases: what should the clinician expect, what should patients be told?显示文摘An awareness of the expected time for therapies to induce symptomatic improvement and remission is necessary for determining the timing of follow-up, disease(re)assessment, and the duration to persist with therapies, yet this is seldom reported as an outcome in clinical trials. In this review, we explore the time to clinical response and remission of current therapies for inflammatory bowel disease(IBD) as well as medication, patient and disease related factors that may influence the time to clinical response. It appears that the time to therapeutic response varies depending on the indication for therapy(Crohn's disease or ulcerative colitis). Agents with the most rapid time to clinical response included corticosteroids, calcineurin inhibitors, exclusive enteral nutrition, aminosalicylates and anti-tumor necrosis factor therapy which will work in most patients within the first 2 mo. Vedolizumab,methotrexate and thiopurines had a longer time to clinical response and can take several months to achieve maximal efficacy. Factors affecting the time to clinical response of therapies included use of concomitant therapy, disease duration, smoking status, disease phenotype and advanced age. There appears to be marked variation in time to clinical response for therapies used in IBD which is further influenced by disease and patient related factors. Understanding the expected time to therapeutic response is integral to inform further decision making, maintain a patientcentered approach and ensure treatment is given an appropriate timeframe to achieve maximal benefit prior to cessation. | Abhinav Vasudevan Peter R Gibson Daniel R van Langenberg | 2017 | World Journal of Gastroenterology2017，23，35： | 4 |
| 7 | Dietary Triggers of Abdominal Symptoms in Patients With Irritable Bowel Syndrome: Randomized Placebo-Controlled Evidence显示文摘 | Susan J. Shepherd Francis C. Parker Jane G. Muir Peter R. Gibson | 2008 | Clinical Gastroenterology and Hepatology2008，，7： | 4 |
| 8 | A Diet Low in FODMAPs Reduces Symptoms of Irritable Bowel Syndrome显示文摘 | Emma P. Halmos Victoria A. Power Susan J. Shepherd Peter R. Gibson Jane G. Muir | 2014 | Gastroenterology2014，，： | 4 |
| 9 | Venous and arterial disease in inflammatory bowel disease显示文摘 | Victoria P Tan Alvin Chung Bryan P Yan Peter R Gibson | 2013 | J Gastroenterol Hepatol2013，，7： | 3 |
| 10 | 慢性难治性咳嗽的管理显示文摘慢性难治性咳嗽(chronic refractory cough,CRC)是指按照指南治疗后仍持续存在的咳嗽。至咳嗽专科门诊就诊的患者中,有20%~46%患有慢性难治性咳嗽,这些患者的生活质量及健康水平受到较大影响。许多术语被用来描述慢性难治性咳嗽,包括最近介绍的咳嗽高敏综合征。它的核心症状为局限于喉部附近区域的刺激性干咳。其症状并不仅限于咳嗽,还可包括癔球症、呼吸困难和发声困难。慢性难治性咳嗽与喉高敏综合征和慢性疼痛综合征具有相同的影响因素,这些相似点有助于我们理解其病理生理机制。慢性难治性咳嗽的病理生理学机制复杂,包括咳嗽反射敏感、中枢敏化、外周敏化和声带矛盾运动,通常发生于病毒感染之后。当导致慢性咳嗽的主要病因被排除(或治疗),而咳嗽症状对于治疗反应不佳时可以诊断为慢性难治性咳嗽。针对慢性难治性咳嗽的治疗,过去的十年中有一些新的发现,包括从功能性发声障碍治疗方法借鉴而来的言语病理学干预,以及作用于神经中枢的神经调节剂(例如加巴喷丁和普瑞巴林)的使用。此外,一些尚在研究中的潜在新型治疗方法也显示出较好的前景。 | Peter G Gibson,director Anne E Vertigan,speech pathologist 戴钰 梁志欣 | 2016 | 英国医学杂志中文版2016，0，6： | 3 |
| 11 | Fructose Malabsorption and Symptoms of Irritable Bowel Syndrome: Guidelines for Effective Dietary Management显示文摘 | Susan J. Shepherd Peter R. Gibson | 2006 | Journal of the American Dietetic Association2006，，10： | 3 |
| 12 | No Effects of Gluten in Patients With Self-Reported Non-Celiac Gluten Sensitivity After Dietary Reduction of Fermentable, Poorly Absorbed, Short-Chain Carbohydrates显示文摘 | Jessica R. Biesiekierski Simone L. Peters Evan D. Newnham Ourania Rosella Jane G. Muir Peter R. Gibson | 2013 | Gastroenterology2013，，2： | 3 |
| 13 | Fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAPs) and nonallergic food intolerance: FODMAPs or food chemicals?显示文摘 | Jacqueline S. Barrett Peter R. Gibson | 2012 | Therapeutic Advances in Gastroenterology2012，，4： | 3 |
| 14 | Esophagectomy for T1 Esophageal Cancer: Outcomes in 100 Patients and Implications for Endoscopic Therapy显示文摘 | Arjun Pennathur Andrew Farkas Alyssa M. Krasinskas Peter F. Ferson William E. Gooding Michael K. Gibson Matthew J. Schuchert Rodney J. Landreneau James D. Luketich | 2009 | The Annals of Thoracic Surgery2009，，4： | 2 |
| 15 | Delayed-Enhancement Cardiovascular Magnetic Resonance Coronary Artery Wall Imaging显示文摘 | Susan B. Yeon Adeel Sabir Melvin Clouse Pedro O. Martinezclark Dana C. Peters Thomas H. Hauser C. Michael Gibson Reza Nezafat David Maintz Warren J. Manning René M. Botnar | 2007 | Journal of the American College of Cardiology2007，，5： | 1 |
| 16 | The development of the nucleus freedom cochlear implant system显示文摘 | James F Patrick Peter A Busby Peter J Gibson | 2006 | Trends in Amplification2006，10，4： | 1 |
| 17 | Mapping SNP-anchored genes using high-resolution melting analysis in almond显示文摘 | Shu-Biao Wu Iraj Tavassolian Gholamreza Rabiei Peter Hunt Michelle Wirthensohn John P. Gibson Christopher M. Ford Margaret Sedgley | 2009 | Molecular Genetics and Genomics2009，，3： | 1 |
| 18 | Eosinophilic esophagitis: A clinicopathological review显示文摘 | Hamish Philpott Sanjay Nandurkar Francis Thien Peter R. Gibson Simon G. Royce | 2015 | Pharmacology and Therapeutics2015，，： | 1 |
| 19 | 925j Optimising post-operative Crohn’s disease management: best drug therapy alone versus colonoscopic monitoring with treatment step-up. The POCER study.显示文摘 | Peter De Cruz Michael A. Kamm Amy L. Hamilton Kathryn J. Ritchie Soula Krejany Alexandra Gorelik Danny Liew Lani Prideaux Ian C. Lawrance Jane M. Andrews Peter A. Bampton Miles Sparrow Timothy H. Florin Peter R. Gibson Henry Debinski Richard B. Gearry Fin | 2013 | Gastroenterology2013，，5： | 1 |
| 20 | Asthma in Pregnancy显示文摘 | Vanessa E. Murphy Peter G. Gibson | 2011 | Clinics in Chest Medicine2011，，1： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员